United Therapeutics
UTHR
391 hedge funds and large institutions have $7.28B invested in United Therapeutics in 2021 Q1 according to their latest regulatory filings, with 71 funds opening new positions, 115 increasing their positions, 151 reducing their positions, and 33 closing their positions.
115% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 33
23% more funds holding in top 10
Funds holding in top 10: 13 → 16 (+3)
11% more capital invested
Capital invested by funds: $6.56B → $7.28B (+$723M)
10% more funds holding
Funds holding: 356 → 391 (+35)
9% more call options, than puts
Call options by funds: $78.3M | Put options by funds: $72.1M
0.79% more ownership
Funds ownership: 97.04% → 97.82% (+0.79%)
24% less repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 151
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$86M |
| 2 |
Swedbank
Stockholm,
Sweden
|
+$68.9M |
| 3 |
PCM
Polaris Capital Management
Boston,
Massachusetts
|
+$63.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$33.8M |
| 5 |
BC
Brahman Capital
New York
|
+$33.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$68.8M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$66.7M |
| 3 |
Renaissance Technologies
New York
|
-$66.6M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$52.1M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$35.7M |
UTHR Hedge Fund Activity: Q1 2021 in Review
391 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q1 2021, worth a combined $7.28B — up 11% from $6.56B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new UTHR positions and 33 closed out — a net gain of 38 holders — while 115 added to existing stakes and 151 trimmed.
The largest buyer was Fuller & Thaler Asset Management, adding an estimated $86M. The largest seller was Citadel Advisors, cutting an estimated $68.8M.
- 391 institutional investors held United Therapeutics (UTHR) as of Q1 2021, up from 356 in Q4 2020.
- Funds reported $7.28B of United Therapeutics stock for Q1 2021, up 11% quarter-over-quarter.
- 71 funds opened new United Therapeutics positions in Q1 2021 and 33 closed out, a net change of +38 holders.
- The largest United Therapeutics buyer in Q1 2021 was Fuller & Thaler Asset Management, an estimated $86M added.
- The largest United Therapeutics seller in Q1 2021 was Citadel Advisors, an estimated $68.8M sold.
Based on aggregated 13F filings for Q1 2021.